HRSA's new 340B Rebate Model Pilot, targeting a January 2027 start, is not a restart of the version that got enjoined last year. It covers a broader drug set, locks down what data manufacturers can request, adds real enforcement teeth for late or improper denials, publishes a specific cost estimate for the first time, and is built on a much more detailed legal record. Manufacturers approved under the original pilot are not automatically carried over. Here is what changed and what to do about it.

Search "340B Beacon rebate model" right now and you will land on three different things: J&J's 2025 shift of Stelara and Xarelto to a rebate process, HRSA's original Rebate Model Pilot Program that was supposed to start January 1, 2026, and the revised pilot HRSA just published for a January 1, 2027 start. They are related, but they are not the same program, and the differences matter for how you plan the next several months. Here is what actually changed between the version that got enjoined and the version on the table now.

‍

The Two Programs People Mean When They Say "Beacon" or “Rebate Model”

Beacon is the name of the IT platform, operated by Second Sight Solutions (the same company behind 340B ESP), that manufacturers used to run 340B rebate claims. It is not a HRSA program. J&J was the first manufacturer to move drugs to a rebate structure through Beacon, ahead of any HRSA-approved pilot. HRSA's own Rebate Model Pilot Program, published August 1, 2025, was a separate, broader federal initiative: eight manufacturers were approved for ten drugs, using Beacon or comparable platforms, with a January 1, 2026 effective date.

That version never launched as planned. A coalition of covered entities sued in the District of Maine, arguing HRSA had not adequately justified the shift away from upfront discounts. The court agreed and issued a nationwide injunction in December 2025. After that ruling held up on appeal, HRSA withdrew the 2025 Pilot rather than keep fighting it, and the court formally vacated the underlying notices in February 2026.

The notice HRSA published this week is not a resumption of that program. It is a new pilot, built specifically to answer the legal problems that sank the first one, with a January 1, 2027 target date. Manufacturers approved under the 2025 version are not automatically carried over. They have to apply again, with plans due by August 24, 2026.

What's Actually Different This Time

• Which drugs are covered. The original pilot ran on the 2026 Medicare Drug Price Negotiation selected drug list only. The new pilot adds the 2027 selected drug list on top of it, so the covered drug set spans two negotiation cycles. HRSA estimates the combined set still represents less than 5.5% of total 340B sales, with the remaining 94.5% staying on the upfront discount model.
• What data manufacturers can ask for. The new notice draws a hard line that the original pilot's public record did not include: purchasing data and encounter-level clinical information are explicitly off-limits. Manufacturers are restricted to a fixed list of pharmacy and medical claims fields, and cash-paying or uninsured claims can be marked "CASH" rather than forced into a health plan field that does not apply.
• How manufacturer non-compliance gets handled. The new pilot sets a specific trigger: if HRSA finds that five percent or more of a sampled batch of claims were denied without acceptable justification, or paid outside the required 10-day window without cause, it can start removing that manufacturer from the pilot. Manufacturers must also publish their denial and dispute data within 30 days of the effective date. None of this level of enforcement detail was part of the original public notice.
• How much this is expected to cost, in dollars. HRSA published a specific number this time: $523,345,680 in total annual administrative cost across all 15,249 covered entities, or roughly $34,320 per entity on average. The original notice did not include a comparable figure.
• The legal groundwork underneath it. The new notice includes a lengthy section walking through alternatives HRSA considered and rejected (enhanced claims modifiers, a clearinghouse model, narrower pilot scopes), plus a formal small-entity impact analysis under the Regulatory Flexibility Act. This is HRSA directly addressing the reasoning gaps the Maine court flagged the first time.
• HIPAA treatment. The new notice adds a dedicated explanation of how claims data submitted through rebate platforms interacts with HIPAA, including when that data counts as de-identified and when disclosure falls under the payment-activities exception. The original notice did not address this publicly.

What Hasn't Changed

The core transaction is the same one covered entities dealt with under the original Beacon rollout: buy at wholesale acquisition cost, dispense to an eligible patient, submit claims data within 45 days, and receive a rebate equal to WAC minus the 340B ceiling price. Manufacturers still have 10 days to pay or deny a claim once a submission is complete. And HRSA's underlying authority to use rebates instead of upfront discounts is not new. It traces back to the original 1992 statute, which has always allowed either mechanism at the Secretary's discretion.

What to Do Now

Do not assume your manufacturer relationships carry over from the 2025 pilot. Confirm separately which manufacturers are applying for this round, since approvals are due by September 24. If you were building a Beacon registration or claims workflow for the original pilot, revisit it against the new data field list rather than assuming it still matches. And if cash flow modeling was already on your to-do list from the first attempt, the 2027 drug list is longer, so it is worth rerunning those numbers rather than reusing last year's estimate.

How RxTrail Handles It

We are tracking which manufacturers reapply under this notice and flagging the ones tied to your purchasing volume. Our job is translating the specific data fields, denial rules, and timelines in this notice into a workflow your team can actually run, and telling you where this version diverges from what you may have already prepared for. Your job is deciding how much to build now versus wait on. We will keep you current on which manufacturers get approved and when.

Frequently Asked Questions

Is Beacon the platform for this new pilot too?

The notice does not name a platform. It requires manufacturers to identify their IT platform and pay for it themselves. Given Second Sight Solutions' existing footprint with Beacon and 340B ESP, it's reasonable to expect it will be used again, but manufacturers could choose differently.

Does J&J's original rebate model on Stelara and Xarelto still apply, or does this replace it?

This notice does not address manufacturer-specific programs directly. It governs the drugs on the 2026 and 2027 Medicare negotiation lists. If Stelara or Xarelto are on those lists and J&J applies to participate, that manufacturer's plan would need to conform to this notice's rules going forward.

If we registered for Beacon under the 2025 pilot, do we need to do anything again?

Likely yes, once manufacturer plans are approved. Registration details, required documentation, and data fields may differ under the new notice, so treat any prior registration as a starting point, not a finished setup.

Could this version also get enjoined?

‍ It's possible, but HRSA built this notice specifically to address the reasoning gaps a court already flagged once. That does not guarantee it survives a challenge, but it is a materially different legal posture than the original.

‍